Evidence map›Paper›PMID 42458482›Full record

ArticleDiagnostic pathology2026

Tissue-based detection of macrophage-associated YAP1-positive material in human acute liver injury: an exploratory immunopathological biopsy series.

Hiroteru Kamimura, Kenya Kamimura, Shuji Terai

Abstract read
In one paragraph

Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hiroteru KamimuraDivision of Gastroenterology and Hepatology, Niigata University Graduate School of Medicine, Dentistry and Health Sciences (Medicine), Niigata University, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan. hiroteruk@med.niigata-u.ac.jp.ORCID https://orcid.org/0000-0002-9135-3092
Kenya KamimuraDivision of Gastroenterology and Hepatology, Niigata University Graduate School of Medicine, Dentistry and Health Sciences (Medicine), Niigata University, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan.
Shuji TeraiDivision of Gastroenterology and Hepatology, Niigata University Graduate School of Medicine, Dentistry and Health Sciences (Medicine), Niigata University, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundYes-associated protein 1 (YAP1), a downstream effector of the Hippo pathway, is implicated in hepatocellular stress, ductular reaction, and tissue repair. Experimental studies suggest that injured YAP1-activated hepatocytes can be cleared by Kupffer-cell phagocytosis, but corresponding human biopsy evidence remains limited.

methodsWe retrospectively analyzed seven adults who underwent clinically indicated liver biopsy within 10 days of initial presentation or referral admission for acute liver injury. Liver biopsy sections were assessed by hematoxylin and eosin staining, periodic acid-Schiff-diastase staining, YAP1 immunohistochemistry, and double immunofluorescence for YAP1 and CD68. Macrophage-associated YAP1-positive structures were operationally defined as YAP1-positive signals located within or immediately adjacent to CD68-positive macrophages in portal or periportal areas. The definition was intended to capture spatial association and was not intended to prove intracellular phagocytosis, molecular co-expression, or endogenous YAP1 expression by macrophages. Associations with peak Model for End-Stage Liver Disease (MELD) score and days to alanine aminotransferase (ALT) normalization were evaluated as exploratory analyses.

resultsThe median age was 52 years, and etiologies included autoimmune hepatitis, primary biliary cholangitis-autoimmune hepatitis overlap, drug-induced liver injury, acute hepatitis B, and idiopathic acute liver injury. Liver biopsy was performed at a median of 5 days (range, 2-10 days) after initial presentation or referral admission. A median of nine portal tracts and five macrophage-associated YAP1-positive structures were evaluated per biopsy, yielding a median YAP1/CD68-positive portal-tract index of 58.3%. ALT normalized after a median of 26 days. The index showed a nominal inverse association with days to ALT normalization (Spearman rho = -0.86, p = 0.014; Pearson r = -0.79, p = 0.034), whereas MELD score was not significantly associated with the index or recovery time. Leave-one-out analyses retained the inverse direction but showed unstable significance because of the very small sample size.

conclusionsIn this small exploratory biopsy series, YAP1-positive material was observed in spatial association with CD68-positive macrophages in early human acute liver injury. The YAP1/CD68-positive portal-tract index showed a hypothesis-generating relationship with biochemical recovery but should not be interpreted as a validated prognostic marker or proof of macrophage-mediated phagocytosis. Larger, etiology-specific studies with standardized biopsy timing, lineage markers, multiplex immunofluorescence, high-resolution imaging, and digital pathology are warranted.

Indexed as

Adaptor Proteins, Signal TransducingLiverLiver DiseasesMacrophagesPhosphoproteinsTranscription FactorsAdultAgedAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersBiopsyCD68 MoleculeFemaleHumansImmunohistochemistryAdaptor Proteins, Signal TransducingAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersCD68 antigen, humanCD68 MoleculePhosphoproteinsTranscription FactorsYAP1 protein, humanYAP-Signaling ProteinsAcute liver injuryCD68Ductular reactionImmunofluorescenceKupffer cellLiver biopsyYes-associated protein 1

Identifiers

PMID42458482
PMCPMC13570499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.